Buy 5-MeO-MiPT (Moxy) Cas 96096-55-8
Buy 5-MeO-MiPT (Moxy) Cas 96096-55-8
5-MeO-MiPT, also known as 5-methoxy-N-methyl-N-isopropyltryptamine or by its nickname Moxy, is an atypical psychedelic drug of the tryptamine and 5-methoxytryptamine families.[1][4][3] It has unique and unusual effects compared to other psychedelic tryptamines.[1][4][7][3][6] At low doses, its effects include stimulation, tactile and sexual enhancement, some MDMA-like entactogenic effects, and introspective and mild perceptual changes with few or no psychedelic visuals or time dilation, whereas at higher doses, it produces 5-MeO-DMT-like classical psychedelic effects.[1][4][7] It is usually taken orally or smoked.[1]
The drug acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors, among others.[8][9][10] It is closely related in chemical structure and effects to 5-MeO-DiPT, and is also related to other tryptamines like 5-MeO-DMT, 4-HO-MiPT, and MiPT.[1][4][7]
5-MeO-MiPT was first described in the literature by Alexander Shulgin and David Repke and colleagues in 1985.[4][6][11] It was later described by Shulgin in greater detail in his 1997 book TiHKAL (Tryptamines I Have Known and Loved).[1] Recreational use of 5-MeO-MiPT is significant but relatively rare.[6] It is often used as a substitute for 5-MeO-DiPT, which has similar effects but was became a controlled substance in the United States in 2003.[6] The Drug Enforcement Administration (DEA) proposed banning 5-MeO-MiPT as well in the 2020s, but later withdrew its proposal amid public opposition.[4] 5-MeO-MiPT, under the developmental code name MSD-001, is being developed for the treatment of psychiatric disorders by Mindstate Design Labs and is in phase 1 clinical trials for this purpose as of 2025.[3][12][13][14][15]
Use and effects
In his book TiHKAL (Tryptamines I Have Known and Loved), Alexander Shulgin lists the dose of 5-MeO-MiPT as 4 to 6 mg orally and 12 to 20 mg smoked.[1][6] A wider recreational dose range of 0.5 to 20 mg or more orally has also been reported however.[4][16][5] Oral doses of 1 to 3 mg have been described as light, 3 to 8 mg as common or moderate, and 8 to 12 mg as strong.[5] Its onset of action when taken orally is described as very rapid, occurring within 15 to 45 minutes, peak effects appear to occur after around 1 to 2 hours, and its duration as 4 to 6 hours.[1][6] However, other sources state its duration as 3 to 8 hours.[4][5] A clinical trial confirmed that 5-MeO-MiPT has an onset of about 30 minutes and that peak effects occur after about 1.5 to 2 hours.[3] Its duration smoked is said to be 2 to 5 hours.[6]
5-MeO-MiPT has been described as having unique and unusual effects relative to other psychedelic tryptamines.[1][4][7] The effects of 5-MeO-MiPT differ depending on whether it is taken orally or smoked and are highly dose-dependent.[1][4] When taken orally at relatively low doses like 4 to 6 mg, it is usually described as not producing psychedelic visuals or related sensory effects and as producing only hints of time dilation.[1][4] However, it is said to produce a stoned state that includes an ease of interpretive fantasy, dream-like perception, intense conceptual thought and philosophical thinking, and mild perceptual effects like altered depth perception, minor wave pattern in peripheral vision, and slightly enhanced auditory acuity.[1] Moreover, the drug is described as producing stimulation, greatly enhanced tactile sensation and eroticism, enhanced music appreciation, tingling, shakes, and mild motor impairment.[1][4] Its head space is described as relatively “shallow”, less confusing, and more easily tolerated compared to classical psychedelics.[4] Its effects have been described by users variably as both pleasant and negative.[1][4]
When smoked, 5-MeO-MiPT is described as having effects similar in many regards to those of 5-MeO-DMT.[1] These effects of smoked 5-MeO-MiPT include a powerful rush (but less intense than 5-MeO-DMT), loss of coherent thought, not much in the way of visuals, closed-eye visuals of moving and colored geometric patterns, intense waves of mental imagery of emotionally infused memories, impressive recall of early memories, intense depersonalization or disorientation of the normal sense of being a person in a body, loss of immediate contact with surroundings, emotional lability including laughing, crying, and vocal outbursts, groaning, writhing, shaking around, and general disorientation.[1] It is described as having a very rapid onset, with the peak phase lasting less than 30 minutes and waves continuing for up to a few hours.[1] It was described by one user as feeling like a hybrid between diethyltryptamine (DET) and 5-MeO-DMT.[1]
5-MeO-MiPT is also known by its nickname “Moxy”[4] and is closely related both in terms of chemical structure and effects to 5-MeO-DiPT (also known as “Foxy Methoxy”).[1][7] These two serotonergic tryptamines at low doses have been described as very aphrodisiac and much more stimulant-like and party drugs than classical psychedelics.[7] However, they have been described as not innately aphrodisiac, but instead as enhancing tactile sensation in a way that lends itself to sex.[7] Matthew Baggott has described 5-MeO-MiPT as having some MDMA-like entactogenic effects at low doses, including tactile enhancement and feelings of empathy, intimacy, and closeness with others, and as producing classical psychedelic effects at higher doses.[17]
Mindstate Design Labs has described 5-MeO-MiPT as the “least psychedelic psychedelic that’s psychoactive”.[3] It is described as being quite psychoactive, but as lacking “hallucinations” and as not producing “mind-bending trips”.[3] The drug was assessed at five different doses (up to at least 10 mg) by oral administration in a phase 1 clinical trial in 47 individuals.[3][18][19] Its effects included heightened emotions, associative thinking, enhanced imagination, and perceptual effects such as brighter colors.[3] However, there were no hallucinations, self-disintegration, oceanic boundlessness, or other typical features of psychedelic experiences.[3] Its onset was 30 minutes and its peak of effects was 1.5 to 2 hours.[3] Mindstate Design Labs has hypothesized that a mild psychedelic experience, as with 5-MeO-MiPT, could still provide therapeutic benefits without overt hallucinogenic effects.[3]
In addition to its use on its own, 5-MeO-MiPT, along with the related tryptamine psychedelic 4-HO-MET, is employed as a component of the MDMA-mimicking Borax combo.[4][20][21][22]
Side effects
Adverse effects of 5-MeO-MiPT include loss of appetite and insomnia.[1] Low-dose 5-MeO-MiPT did not cause any serious histopathological effects on the liver, kidney, and brain. High doses induce apoptotic cell death through caspase activity especially in some parts of the organs.[23] There is no known documentation of death attributed to the use of 5-MeO-MiPT alone.[4]
Reviews
There are no reviews yet.